Navigation Links
'It takes 2 to know 1': Shared experiences change self-recognition
Date:1/7/2009

Looking at yourself in the mirror every morning, you never think to question whether the person you see is actually you. You feel familiarat home with your own unique self image. After all, you have been sporting the same old face for years. An innovative study published December 24, 2008 in the online, open-access, peer-reviewed journal PLoS ONE, by Dr Manos Tsakiris, Department of Psychology, Royal Holloway, University of London, challenges this common-sense notion about our own self image. The study shows for the first time that the image we hold of our own face can actually change through shared experiences with other people's faces.

The study reveals that recognition of our own face is not as consistent as we might think. The participants' ability to recognise their own face changed when they watched the face of another person being touched at the same time as their own face was touched, as though they were looking in a mirror. Specifically, when asked to recognize a picture of their own face, the picture that people chose included features of the other person they had previously seen. This did not happen when the two faces were touched out of synchrony.

Sharing an experience with another person may change the perception we have of our own self, such as the recognition of our own face. "As a result of shared experiences, we tend to perceive other people as being more similar to us, and this applies also to the recognition of our own face. This process may be at the root of constructing a self-identity in a social context," says Dr Tsakiris who led the study funded by the Economic and Social Research Council, UK.

The findings imply that shared experiences may influence the way we perceive ourselves and possibly the way we interact with others. Dr Tsakiris explains, "If I feel that you are more like me, I might then behave to you in a different way. We now test whether shared experiences can make us stereotype others les
'/>"/>

Contact: Dr. Manos Tsakiris
manos.tsakiris@rhul.ac.uk
44-178-427-6266
Public Library of Science
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Free will takes flight: how our brains respond to an approaching menace
2. New AHIP Report Takes a Ten Year Look at the Unintended Consequences of State Efforts to Change the Insurance Market
3. Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival
4. Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts
5. Small Town Doctor Takes on Giants in Consumer Healthcare
6. Help is Available for Smokers Who Want to Quit as Minnesotas Smoke-Free Law Takes Effect Oct. 1
7. Growing Healthy with School Gardens Takes Root in Los Angeles Saturday
8. Randy Jackson Takes Aim at Diabetes
9. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
10. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
11. Morrison Takes Aim at Underage Drinking in New Radio Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2
Other Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9